// App-Quantinova.ai

BSH19‐PO‐112 : UK real world experience: european post‐approval safety study (pass) in relapsed/refractory multiple myeloma patients treated with pomalidomide

Researchers

Presenter

  • G. Jackson

Principal Investigators

  • C. Kyriakou

  • A. Whiteway

  • S. Narat

  • K. Saravanamuttu

  • E. Kueenburg

  • B. Rosettani

  • M. Hamilton

  • P. Williams

  • H. Sati

  • J. Tighe

  • S. Feyler

  • J. Ashcroft

  • S. Mittal

Medical Centers

  • Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

  • Northwick Park Hospital, London North West Healthcare NHS Trust, Harrow

  • North Bristol NHS Trust, Southmead, Bristol

  • Western Sussex Hospitals Trust‐ Worthing, Worthing

  • United Lincolnshire Hosps, Lincoln, United Kingdom

  • Celgene, Boudry, Switzerland

  • Celgene Ltd, UK and ireland, Uxbridge

  • Singleton Hospital, Abertawe Bro Morgannwg University Health Board,Swansea, UK

  • Aberdeen Royal Infirmary, Aberdeen

  • Huddersfield Royal Infirmary, Calderdale and Huddersfield NHS, Huddersfield

  • Pinderfields Hospital, Mid Yorkshire NHS Trust, Wakefield

  • Southampton General Hospital, Southampton, United Kingdom

Locations

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pomalidomide

  • CC-4047

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02164955

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved